Lidokainklorid Galenika (Lidocaine Hydrochloride)

Lidokainklorid is a local anesthetic used in procedures that require regional nerve blockade.

• Minor surgical procedures: provides local anesthesia to reduce pain during the operation.
• Epidural analgesia: delivers regional pain relief during labor or surgical procedures.
• Infiltration anesthesia: numbs targeted tissue for diagnostic or therapeutic interventions.
• Intradermal testing: used as a reagent for skin allergy testing.

• Lidocaine Hydrochloride blocks voltage‑gated sodium channels in neuronal membranes, preventing the initiation and propagation of nerve impulses. By stabilizing the neuronal membrane, it inhibits depolarization, resulting in reversible loss of sensation in the area where it is administered.

Lidokainklorid may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Transient burning or stinging at the injection site
• Mild dizziness or light‑headedness
• Nausea or metallic taste
• Localized swelling or erythema

Serious or Rare Side Effects

• Allergic reactions such as rash, angioedema, or anaphylaxis
• Cardiac arrhythmias, including ventricular tachycardia
• Central nervous system toxicity (seizures, loss of consciousness)
• Methemoglobinemia, a rare blood disorder affecting oxygen transport

Before using Lidokainklorid, consider the following safety measures.

• Allergy assessment: verify no known hypersensitivity to amide‑type local anesthetics.
• Cardiovascular status: avoid in patients with severe heart block or conduction disorders.
• Dosage limits: adhere to recommended maximum dose to prevent systemic toxicity.
• Concurrent CNS depressants: monitor for enhanced sedation when combined with other depressants.
• Pregnancy and lactation: use only if the benefit outweighs the potential risk (category unknown).
• Store at room temperature: keep in the original container, protect from moisture and light.

Lidokainklorid can interact with other medicines, altering its safety profile.

Major Interactions (Avoid)

• Class I antiarrhythmics (e.g., quinidine, procainamide): may increase lidocaine plasma levels.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): can raise systemic exposure.
• Concurrent use of other local anesthetics: additive risk of toxicity.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may potentiate cardiac effects of lidocaine.
• Diuretics such as furosemide: may reduce plasma protein binding, increasing free drug.
• General anesthetics (e.g., propofol): may enhance central nervous system depression.